FDA’s Autor Moves To Mylan: Company’s Gain May Also Be Company’s Loss
Executive Summary
While Mylan wants Autor to help push quality improvement efforts around the world, her departure from FDA may affect implementation of similar plans at the agency.
You may also be interested in...
Former FDA Deputy Commissioner Autor Leads Regulatory Affairs Consultancy
Deborah Autor will build on Healthcare Innovation Catalysts’ cross-functional technical expertise, furthering its role as an advisor in the private and public sectors as its first CEO.
Leader Of US FDA's EU Mutual Recognition Effort Departs For Industry
Dara Corrigan will become Fresenius-Kabi’s VP for global affairs and policy.
Mylan Grabs More FDA Globalization Talent
Steve Lynn, director of CDER’s Office of Manufacturing and Product Quality, will take an executive global compliance position.